This study tests a new drug called Tegoprubart (also known as AT-1501) for people getting a kidney transplant. It compares Tegoprubart to another drug named tacrolimus. The goal is to see which drug better prevents the body from rejecting the new kidney.

The study is randomized (patients are randomly assigned to a group) and open-label (both doctors and patients know which treatment is given). It involves up to 120 people who are getting their first kidney transplant. Participants will either receive Tegoprubart or tacrolimus, along with other standard medicines like steroids and mycophenolate to help keep the new kidney healthy.

• Participants must be 18 or older and getting their first kidney transplant.
• Study involves multiple visits to the clinic for monitoring.
• Participants must agree to use contraception during the study and for 90 days after.

People can't join if they already use certain medicines or have specific medical conditions, like blood clotting issues or certain immune responses.